Silence Therapeutics (NASDAQ:SLN - Get Free Report) is anticipated to release its earnings data before the market opens on Wednesday, March 12th. Analysts expect Silence Therapeutics to post earnings of ($0.16) per share for the quarter. Persons that are interested in registering for the company's earnings conference call can do so using this link.
Silence Therapeutics Price Performance
Shares of NASDAQ:SLN traded up $0.11 during trading hours on Friday, hitting $4.85. 197,333 shares of the company's stock traded hands, compared to its average volume of 307,544. Silence Therapeutics has a 1 year low of $4.06 and a 1 year high of $27.72. The business has a fifty day moving average price of $5.44 and a 200-day moving average price of $11.48. The firm has a market capitalization of $145.16 million, a P/E ratio of -3.09 and a beta of 1.08.
Analyst Ratings Changes
Several brokerages have issued reports on SLN. HC Wainwright restated a "buy" rating and set a $75.00 target price on shares of Silence Therapeutics in a research report on Friday. The Goldman Sachs Group decreased their price target on shares of Silence Therapeutics from $6.00 to $4.00 and set a "sell" rating for the company in a research note on Tuesday. BMO Capital Markets decreased their price target on shares of Silence Therapeutics from $67.00 to $25.00 and set an "outperform" rating for the company in a research note on Tuesday. William Blair reaffirmed an "outperform" rating on shares of Silence Therapeutics in a research note on Tuesday, November 19th. Finally, Morgan Stanley decreased their price target on shares of Silence Therapeutics from $49.00 to $45.00 and set an "overweight" rating for the company in a research note on Wednesday. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company's stock. Based on data from MarketBeat.com, Silence Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $40.67.
Check Out Our Latest Analysis on Silence Therapeutics
Silence Therapeutics Company Profile
(
Get Free Report)
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.
Further Reading
Before you consider Silence Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Silence Therapeutics wasn't on the list.
While Silence Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
